Research Article
Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma
Table 3
Characteristics of patients with ORR (
) and non-ORR (
).
| Characteristic | No. of ORR | No. of non-ORR | value |
| Gender | | | | Male | 14 | 26 | | Female | 8 | 12 | 0.705 | Age (years) | | | | ≥20 | 6 | 12 | | <20 | 16 | 26 | 0.726 | ECOG PS | | | | 0 | 20 | 30 | | 1 | 2 | 8 | 0.231 | Site of primary tumor | | | | Femur and tibia | 12 | 26 | | Other | 10 | 12 | 0.282 | Size of primary tumor (cm) | | | | ≥5 | 17 | 31 | | <5 | 5 | 7 | 0.688 | Response to neoadjuvant chemotherapy | | | | Good | 3 | 7 | | Poor | 19 | 31 | 0.632 | Location of metastasis | | | | Lung | 18 | 32 | | Others | 4 | 6 | 0.811 | Infusion of TIL numbers | | | | ≥ | 20 | 15 | | < | 2 | 23 | 0.000 | Infusion of CD8+TIL percentage | | | | ≥60% | 19 | 11 | | <60% | 3 | 27 | 0.000 | Infusion of CD8+PD1+TIL percentage | | | | ≥10% | 4 | 21 | | <10% | 18 | 17 | 0.005 | Infusion of CD4+FoxP3+TIL percentage | | | | ≥20% | 2 | 19 | | <20% | 20 | 19 | 0.001 |
|
|